AiCuris Announces AIC246 to be Successful in Treatment of Multiorgan HCMV Disease
AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-or…
AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-or…
. - Promising Phase II study results with pipeline product PA21 - Phase III study to start soon in collaboration with F…
clinicalprojects international GmbH (CPI), an independent contract research organization, announced today that the compa…
Board elects new CEO to molecular diagnostics company SIRS-Lab GmbH SIRS-Lab GmbH, the molecular diagnostics company foc…
Ascenion GmbH announces today that it is taking an equity position in MBiotec GmbH, a biopharmaceutical company that has…
SIRS-Lab, a leader in molecular diagnostics, is delighted to announce the appointment of Dr. Edward Currie as Executive…
Jena, Dec 3rd, 2008 SIRS-Lab today announced that the EU regulatory authorities have granted the CE mark for VYOO, a mol…
/pressemitteilung/pdf/97499/meldung.pdf